President Biden is confirming the biopharma industry’s worst fears with his proposal to expand the Medicare price negotiation program established by the Inflation Reduction Act to drugs even earlier in their lifecycle. The plan is included in the president’s federal budget proposal for 2024, to be formally unveiled on 9 March.
The policies are not likely to advance in Congress as long as Republicans control the House. But the fact that...